NaDeNo seeks funding ahead of clinical entry

With a base at AstraZeneca’s BioVentureHub, NaDeNo Nanoscience was on home turf when Nordic Life Science Days brought the industry together.

“It’s an exciting stage for the company as the technology moves from preclinical to clinical development,” say Annbjørg Eide Falck and Jens Bjørheim from NaDeNo Nanoscience.

Read the full story (in Norwegian) at: https://medwatch.no/nyheter/legemidler_biotek/article18633421.ece

Annbjørg Falck (Co-founder & CEO) and Jens Bjørheim (CMO) at NLSDays 2025 in Gothenburg, Sweden.